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Biomaterials hold promise for therapeutic applications in the central nervous system (CNS).
Little is known about molecular factors that determine CNS foreign body responses (FBRs)
in vivo, or about how such responses influence biomaterial function. Here, we probed these
factors in mice using a platform of injectable hydrogels readily modified to present interfaces
with different physiochemical properties to host cells. We found that biomaterial FBRs mimic
specialized multicellular CNS wound responses not present in peripheral tissues, which serve
to isolate damaged neural tissue and restore barrier functions. We show that the nature and
intensity of CNS FBRs are determined by definable properties that significantly influence
hydrogel functions, including resorption and molecular delivery when injected into healthy
brain or stroke injuries. Cationic interfaces elicit stromal cell infiltration, peripherally derived
inflammation, neural damage and amyloid production. Nonionic and anionic formulations
show minimal levels of these responses, which contributes to superior bioactive molecular
delivery. Our results identify specific molecular mechanisms that drive FBRs in the CNS and
have important implications for developing effective biomaterials for CNS applications.
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B iomaterials are under widespread investigation for experi-mental and therapeutic applications in the central nervoussystem (CNS)1. Biomaterials with specialized properties
have been incorporated in implantable neuroprostheses that are
used clinically for recording neuronal activity and stimulating
neural circuits in the CNS2,3. In addition, injectable biomaterial
hydrogels are used extensively as experimental tools to provide
local delivery of growth factors, for example, to attract injured
and regenerating axons to grow across CNS lesions4,5 as well as to
afford molecular and physical support to co-suspended neural
progenitor cells to improve survival and modulate differentiation
upon grafting into the CNS6–8.
Although various classes of biomaterials may be used for
applications in the CNS, synthetic, or naturally derived polymers
are the predominate choice for directly interfacing with host CNS
tissue and cells9,10. For neuroprostheses, diverse classes of poly-
mers are used as the outer substrates or coatings for metal elec-
trodes intended to improve device insertion and long-term
performance in vivo10,11. In addition, new devices based on
electrically conducting polymers are also being developed12. For
hydrogels, considerable progress has been made in synthesizing
new polymers with tunable physiochemical properties to achieve
spatial and temporal control of molecular release or provide
unique support to co-suspended cells13–16.
Despite innovations in the many engineering and design
aspects of biomaterials that are used for CNS applications, little
is known about factors that determine the CNS foreign body
response (FBR) in vivo to these materials, or how such
responses influence function. Assessments of cytotoxicity and
biocompatibility of biomaterial interfaces with host cells, or
biomaterial functions such as molecular release kinetics are
often evaluated primarily in vitro or through subcutaneous
implantation in vivo17,18. However, in vitro observations and
the FBR associated with subcutaneously implanted biomaterials
need not predict in vivo performance in the CNS, where there is
a highly specialized and unique multicellular wound response
that serves to isolate damaged tissue and restore barrier
functions.
Substantial advances have been made in understanding the
CNS wound response, which can inform the study of CNS FBRs.
The CNS wound response is a biologically conserved process
whereby perturbations of CNS tissue lead to dynamic multi-
cellular interactions that efficiently isolate regions perceived as
damaged, infected, or diseased to protect adjacent viable neural
tissue and permit recruited inflammation to resolve potentially
noxious elements5,19–21. This multicellular CNS wound response
generates tissue lesions characterized by distinct non-neural and
neural cellular compartments in which non-neural lesion cores
with stromal and inflammatory cells are segregated from adjacent
spared and viable neural tissue by an astroglial border22. The
cellular responses to materials perceived as foreign are likely to be
related to this multicellular natural wound response23, but the
study of CNS FBRs to biomaterials in vivo has not kept pace with
recent advances made in the cell biology of CNS injury. There is a
need to better understand: (i) key cellular interactions of CNS
FBRs to biomaterials, (ii) biomaterial properties that influence the
severity of CNS FBRs, and (iii) the extent to which CNS FBRs
influence biomaterial function in vivo. Here, we evaluated these
parameters by comparing multiple synthetic and naturally
derived hydrogel-based biomaterials.
As a platform to determine the effects of specific molecular
features on biomaterial-evoked FBRs, we used synthetic, diblock
copolypeptide hydrogels (DCH), which can be readily modified to
present interfaces with different representative physiochemical
properties to host cells whilst retaining consistent polymer chain
lengths and mechanical properties8,24,25. These shear-thinning,
physical hydrogels can be administered to focal CNS regions in a
minimally invasive manner by infusion through narrow cannulae
ensuring that minimal tissue damage is induced by the implan-
tation of the biomaterial that could otherwise confound the CNS
FBR evaluation of the host-biomaterial interface24–26. Moreover,
because these hydrogels can be prepared to exhibit the same
mechanical stiffness as CNS tissue (ca. 100–400 Pa)25, they can be
fixed and processed in situ and retain their intimate contact with
immediately adjacent host cells so that directly contiguous
biomaterial–host interfaces can be examined and quantified in
detail. This type of analysis is not possible with rigid, mechani-
cally stiff or hydrophobic materials and coated electrodes that
must be removed before tissue sectioning, because this removal
invariably also disrupts the immediate material-cellular interfaces,
which cannot then be evaluated.
We benchmarked our findings using DCH that present phy-
siochemically defined interfaces against various commonly used,
commercially available and previously CNS-tested hydrogel for-
mulations. We compared biomaterial FBRs with naturally evoked
CNS wound responses modeled using chemically induced
ischemic strokes that were equivalent in size to the hydrogel
depots. We tested the effects of CNS FBRs on hydrogel functions
when hydrogels were either injected into healthy uninjured brain
or into subacute stroke lesions. We show that CNS FBRs to
biomaterials mimic conserved elements of CNS wound healing
and exists on a definable severity spectrum characterized by the
presence or absence of specific different types of non-neural cells.
We show that the nature and intensity of CNS FBRs are deter-
mined by definable material properties and elicit quantifiable
differences in hydrogel functions such as resorption and mole-
cular delivery in both healthy and stroke injured brains. Lastly, we
found that severe FBRs provoked by certain hydrogels injected
into CNS strokes can disrupt naturally occurring reparative
wound responses.
Results
Hydrogel-evoked FBRs vary and mimic CNS wound responses.
We first compared cellular profiles of mild or severe CNS wound
responses with FBRs of two structurally similar, synthetic, diblock
copolypeptide hydrogels (DCH) that present either strongly
cationic (DCHK) or nonionic (DCHMO) interfaces to host cells
(Fig. 1a). Lysine-based DCHK and methionine sulfoxide based
DCHMO are both well tolerated in vivo8,25, but exhibit noticeably
different FBRs. For comparison, mild or severe CNS wound
responses were induced by injection of innocuous phosphate
buffered saline (PBS), or N5-(1-iminoethyl)-l-ornithine (L-NIO)
solution that creates a small focal ischemic stroke27. PBS,
DCHMO, DCHK, or L-NIO were injected into caudate putamen
(CP) of mouse forebrain (Fig. 1b). The CP site is easily accessible,
allows for consistent and reproducible hydrogel injections that are
well tolerated by the mice, and is composed of neural tissue with
neuronal cell bodies, myelinated axon bundles and a diversity of
neuroglial making it an advantageous location for standardized
CNS FBR assessments25. Hydrogel FBRs and wound responses
were characterized with immunohistochemistry (IHC) for CD13
to identify non-neural cells including stromal and peripheral
myeloid lineage cells recruited as part of the sterile inflammatory
response to tissue damage28. CD13 positively identifies the full
temporal range of non-neural tissue remodeling from acute
inflammation through to chronic fibrotic lesion formation. In the
healthy uninjured mouse brain, CD13 is expressed by pericytes
and perivascular fibroblasts along cerebrovasculature and
meningeal fibroblasts29 (Supplementary Fig. 1a–d). CD13 is not
expressed by neuroglia or neurons. Staining for glial fibrillary
acidic protein (GFAP) identified reactive and border-forming
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astrocytes30, P2RY12 identified CNS microglia and NeuN iden-
tified viable neurons.
At 1 week after injections, (i) PBS infusions were detectible as
small areas of GFAP-positive reactive astrocytes; (ii) nonionic
DCHMO and cationic DCHK, exhibited similarly sized deposits;
and (iii) L-NIO created sharply demarcated areas of infarcted
tissue equivalent in size to hydrogel deposits (Fig. 1c). DCHMO
and DCHK deposits and L-NIO infarcts were all surrounded by
similarly appearing borders of GFAP-positive astrocytes that
clearly separated neural tissue containing NeuN-positive neurons
from non-neural cores with CD13-positive cells and hydrogels




























Fig. 1 Hydrogel-evoked FBRs vary and exhibit cellular features of CNS wound response. a Schematic and chemical structures of synthetic hydrogels used
as tools to study CNS FBR. b Experimental model of in vivo injections into caudate putamen (CP) of mouse forebrain. c, d Survey and detail images of
stromal and inflammatory cells (CD13), astrocytes (GFAP), and neurons (NeuN) at 1 week after injections of PBS, hydrogels, or L-NIO-induced stroke.
e–g Quantification of total immunohistochemical staining. e Total CD13 in CP. not significant (NS), ***P < 0.0001 versus PBS injection, one-way ANOVA
with Bonferroni. f Total CD13 in either non-neural or neural tissue compartments. NS or ***P < 0.0001 versus PBS injection, two-way ANOVA with
Bonferroni. g Total GFAP in CP. NS or ***P < 0.0001 versus DCHMO, one-way ANOVA with Bonferroni. All graphs are mean ± s.e.m with individual data
points superimposed showing n= 10, 10, 12, and 4 mice per group for PBS, DCHMO, DCHK, and L-NIO, respectively. AU arbitrary units, G hydrogel, IC
internal capsule.
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PBS injections or at interfaces between DCHMO and host. By
contrast, a dense CD13-positive cell capsule, 164 ± 19 µm in
thickness, had completely surrounded and infiltrated the margins
of DCHK deposits, whereas CD13-positive cells had entirely filled
L-NIO infarcts (Fig. 1c, d). Similar CD13-positive cell accumula-
tion and non-neural/neural cell compartmentalization was
observed 1 week after forebrain stab injury through cerebral
cortex (Supplementary Fig. 1e). Quantification showed that total
CD13 levels across the different compartments of infusion sites
and adjacent neural tissue were similar after PBS and DCHMO
and were significantly higher after DCHK and L-NIO (Fig. 1e;
Supplementary Fig. 2). Notably, the significant increases in CD13
levels after DCHK and L-NIO were confined to central non-
neural tissue compartments of hydrogel plus infiltrating cells, and
there was no significant difference in CD13 levels in surrounding
neural tissue (defined as tissue containing neuroglia and neurons)
adjacent to PBS, DCHMO, DCHK, or L-NIO (Fig. 1f). Moreover,
although GFAP levels were significantly lower adjacent to PBS
injections, there was no significant difference in GFAP levels
adjacent to DCHMO, DCHK, or L-NIO (Fig. 1g).
These findings show that DCH-based hydrogels presenting
precisely defined cationic (DCHK) or nonionic (DCHMO)
interfaces to host cells exhibit FBRs whose cellular profiles and
compartmentalization mimic those of normal CNS wound
responses that are prominent or minimal, respectively, and that
the FBR to different hydrogels can vary significantly. These
findings also suggested that hydrogel surface chemistry and
properties such as charge may influence hydrogel FBR, which we
investigated next.
FBRs vary with definable hydrogel properties. We next char-
acterized FBRs to various cationic, anionic, and nonionic hydro-
gels. We manufactured DCH that presented different polar side
chains to interface with host cells but maintained consistent poly
(L-leucine) hydrophobic blocks8,24,25 (Supplementary Fig. 3a, b).
We compared these DCH with various commercially available
formulations commonly used in CNS applications: methylcellu-
lose (MC)31, a hyaluronic acid/methylcellulose blend (HAMC)32,
and a chitosan/β-glycerophosphate (CHIT) system33. Hydrogels
with comparable mechanical properties (see ref., 8,25,34 and Sup-
plementary Fig. 3c) were injected into mouse forebrain (Fig. 1b),
and cellular FBR profiles were first characterized with IHC for
CD13, GFAP, and NeuN (Fig. 2; Supplementary Figs. 2–5).
Qualitative and quantitative examination showed that nonionic
MC, like nonionic DCHMO, exhibited barely detectable levels of
CD13-positive cells at interfaces with host tissue (Fig. 2a, c;
Supplementary Fig. 4a). Moreover, anionic hydrogels HAMC as
well as glutamate (E) inclusive DCHE and DCHMOE15 also
exhibited barely detectable levels of CD13-positive cells at host
interfaces (Fig. 2a, c; Supplementary Fig. 4a). However, in striking
contrast, cationic hydrogels, DCHK, DCHMM, DCHMOK15,
DCHMOK10, and CHIT all exhibited large rims of CD13-
positive cells infiltrating into deposits around their entire host
interface and had significantly higher CD13 levels in central non-
neural compartments, which did not differ in magnitude across
different cationic hydrogels (Fig. 2b, c; Supplementary Fig. 4b).
To directly probe the relationship between cationic charge and
FBR, we incorporated variable amounts of lysine (K) into
nonionic DCHMO as a statistical copolymer8 (Supplementary
Fig. 3b). DCHMOK15 and DCHMOK10 both exhibited outer rims of
infiltrating CD13 cells similar to DCHK, but with more cells
infiltrating into the deposit center, suggesting that small amounts
of dispersed cationic charge attracted CD13 cells, whereas dense
charge in DCHK prevented these same cells from distributing
throughout the bulk of the material. In addition, we generated
cationic, methyl-sulfonium-based DCHMM (Supplementary
Fig. 3b)8, which also exhibited a rim of infiltrating CD13 cells
similar to DCHK, but in addition exhibited many DAPI-positive
but CD13-negative cells that formed a distinct and separated
layer of cells that directly interfaced with the hydrogel
deposit surface (Fig. 2b). Similar CD13-negative cells at the
material interface were not obviously present in other DCH,
but were present within CHIT deposits (Fig. 2b), suggesting a
distinct cellular infiltrate requiring further characterization as
conducted below.
These findings show that hydrogel FBRs vary with definable
hydrogel properties and implicate cationic charge presented at
material interfaces with host tissue as a major factor determining
FBR severity. At interfaces with host tissue, cationic materials
exhibited a significantly greater loss of neural tissue containing
NeuN-positive neurons in the FBR non-neural tissue zone that
immediately surrounded depots, resulting in overall larger lesions
and greater loss of viable neuropil (Fig. 2d; Supplementary Fig. 5).
Remarkably, despite significantly elevated CD13 in the non-
neural compartments of cationic hydrogels (Fig. 2a–c), there was
no significant difference in either CD13 (Fig. 2d; Supplementary
Fig. 5) or GFAP (Fig. 2e) levels, and no detectable quantitative
difference in NeuN-positive neuron density (Supplementary
Fig. 5), in the neuropil adjacent to either cationic, nonionic or
anionic hydrogels, suggesting that neural tissue beyond the
interface between hydrogel and host was not substantively
differentially impacted. The unexpected finding that GFAP levels
were indistinguishable in neural tissue adjacent to hydrogels that
evoked markedly different FBR at host interfaces indicates that
GFAP staining is not a sensitive or sufficient marker with which
to evaluate and differentiate FBRs.
Hydrogel FBRs differ in inflammatory cell recruitment/per-
sistence. To discriminate among diverse innate-immune inflam-
matory cells involved in hydrogel FBRs, we used IHC for:
(i) CD45 to identify leukocytes and reactive CNS microglia35;
(ii) Iba-1 to identify blood-borne monocytes/macrophages and
CNS microglia35; (iii) P2RY12 to identify only microglia20,36,37;
(iv) Ly6B2 to identify neutrophils21; and (v) CD13 to identify
myeloid lineage peripheral inflammatory cells such as monocytes
and macrophages or fibroblast lineage cells (Fig. 3)28. We
examined combinations of these markers at 1 week after hydrogel
injections (Fig. 1b).
For all hydrogels, the neural tissue immediately adjacent to
deposits contained reactive, CNS-derived microglia that were Iba-
1-, CD45-, and P2RY12-positive and CD13-negative that
intermingled with astrocytes and neurons, remained within the
neural tissue compartment and did not detectably infiltrate into
any hydrogel (Fig. 3a, b; Supplementary Fig. 6a). P2RY12
expression was reduced in reactive microglia that dispersed
directly within forming astroglia borders. Immediately abutting
these microglia, hydrogel deposits exhibited variable intensities of
inflammatory cell infiltrates that were CD45- and CD13-positive,
and P2RY12-negative, and were peripherally derived myeloid
lineage leukocytes and not CNS microglia (Fig. 3a, b, Supple-
mentary Fig. 6a, b). A comparable segregation of blood-borne
inflammatory cells into a non-neural tissue compartment away
from neural tissue was also observed for the L-NIO stroke lesion
(Supplementary Fig. 6c).
Different hydrogels exhibited remarkable variation in both the
intensity and cellular phenotype of the blood-borne inflammatory
response that they attracted. Non-ionic DCHMO, which displayed
a FBR comparable to all the other nonionic and anionic hydrogels
evaluated, attracted only rare infiltrating CD45-positive leuko-
cytes at interfaces with host tissue, and these were macrophage
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lineage (Iba-1-positive and CD13-positive) (Figs. 2a, 3a, b;
Supplementary Fig. 6a). In contrast, cationic DCHK and DCHMM
both attracted thick rims of infiltrating macrophage lineage cells
(CD45-positive, Iba-1-positive, and CD13-positive) along their
entire host interfaces (Figs. 2b, 3a, b; Supplementary Figs. 4, 6a).
Immunohistochemical staining also revealed that the thick layers
of DAPI-positive and CD13-negative cells infiltrating into
DCHMM and CHIT (Fig. 2b) were leukocytes (CD45-positive),
but were not macrophage lineage (Iba-1-negative) (Fig. 3a), and
instead were highly phagocytic and cytotoxic Ly6B2-positive
neutrophils (Fig. 3b, c; Supplementary Fig. 6b). In striking
contrast, nonionic DCHMO and weakly cationic DCHMOK10 or
anionic DCHMOE15, contained no detectable Ly6B2-positive
neutrophils, whereas strongly cationic DCHK attracted a few of
these cells (Fig. 3c, d; Supplementary Fig. 6a).
To test whether inflammatory response intensity correlated
directly with strength of cationic charge at hydrogel surfaces, we
measured zeta potentials of DCH hydrophilic polymer chains.
DCHK, containing homopolymers of lysine, had a significantly
greater positive charge at physiological pH than DCHMM
(containing statistical copolymers with 10% uncharged alanine)
due to a higher total number of charged side chain groups along
each hydrophilic chain (Supplementary Fig. 6d). However, DCHK
had significantly lower levels of neutrophils and equivalent levels
of macrophages compared to DCHMM (Fig. 3d). Non-ionic
DCHMO had no detectable charge, no infiltration of neutrophils
and only rare macrophages (Fig. 3a–c; Supplementary Fig. 6d).
Persistence of peripheral inflammatory cells at hydrogel
deposits was evaluated at 3 weeks after injection (Supplementary
Fig. 7a, b). Notably, while Ly6B2-positive neutrophils were mostly
resolved at CHIT deposits by 3 weeks, thick rims of these acute
inflammatory cells were sustained at DCHMM deposits with a
distribution that was not obviously different to that at 1 week.
DCHMM deposits also remained largely unresorbed at 3 weeks,
whereas CHIT injections were completely infiltrated by cells at
this timepoint (Supplementary Fig. 7c).
These findings show that the intensity and duration of the
inflammatory cell components of CNS FBRs varied markedly in
response to deposits of different hydrogels and that cationic
charge at material–host interfaces is an important factor in
attracting blood-borne phagocytic leukocytes. Nevertheless,
charge magnitude alone does not determine the nature or
distribution of phagocytes attracted.
Hydrogel FBRs involve stromal cells and fibrosis. To char-
acterize fibrosis associated with hydrogel FBRs, we compared a
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Fig. 2 Hydrogels that present cationic interfaces with host cells exhibit increased FBR severity. a, b Survey images of stromal and inflammatory cells
(CD13), astrocytes (GFAP), and all cell nuclei (DAPI) at 1 week after injection of nonionic and anionic a, and cationic b hydrogels. c–e Quantification of total
immunohistochemical staining. c, d Total CD13 in non-neural c and neural d tissue compartments. not significant (NS), ***P < 0.0001, two-way ANOVA
with Bonferroni. e Total GFAP in caudate putamen, NS, one-way ANOVA with Bonferroni. Graphs are mean ± s.e.m with individual data points showing n=
10, 6, 5, 5, 6, 12, 5, 5, 5, 5 mice per group for DCHMO, DCHE, DCHMOE15, HAMC, MC, DCHK, DCHMM, DCHMOK15, DCHMOK10, and CHIT, respectively.
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(DCHMO) to a representative hydrogel with a pronounced but
focal rim of CD13 cells (DCHK) using IHC for cell surface and
extracellular matrix molecules, collagen-1a1, fibronectin, laminin,
and galectin-3 with staining for CD13 at various times after
hydrogel injections (Figs. 1b, 4a–e). Collagen-1a1, fibronectin,
and laminin demarcate stromal cells38, whereas galectin-3 can
demarcate multiple cell types including stromal and inflamma-
tory cells39–41. In uninjected normal neural tissue, (i) CD13-
stained stromal cells along blood vessels and at the meninges, (ii)
collagen-1a1 and laminin lightly decorated cell surfaces along
blood vessels and around neurons, (iii) fibronectin was present at
large vessels and at the meninges, and (iv) galectin-3 was essen-
tially undetectable42 (Supplementary Fig. 8a).
At 1 week after injection, tissue adjacent at interfaces with
nonionic DCHMO exhibited staining for collagen-1a1 and laminin
only along blood vessels in a manner similar to normal neural
tissue, whereas fibronectin and galectin-3 were moderately
elevated in narrow rims along host–gel interfaces (Fig. 4a, c–e).
In contrast, the thick capsule of CD13-positive cells circumscrib-
ing cationic DCHK exhibited significantly greater levels of
collagen-1a1, laminin, fibronectin, and galectin-3 (Fig. 4b, c).
Around DCHK, galectin-3 was robustly expressed by essentially
all CD13-positive cells, whereas collagen-1a1, laminin, and
fibronectin demarcated subsets of stromal cells in outer margins
(Fig. 4b) that interfaced directly with the forming astrocyte
limitans border. An interior layer of CD13- and galectin-3-
positive but collagen-1a1, fibronectin, and laminin-negative cells,
likely peripheral inflammatory cells, interacted directly with the
DCHK surface (Fig. 4b). This inflammatory and fibrotic cell
stratification around DCHK is reminiscent of the cellular
organization in CNS abscesses and traumatic injury lesions40,43.
CD13- and galectin-3-positive cells persisted chronically in the
non-neural tissue compartment of resorbed DCHK for at least
6 weeks (Fig. 4f). Interestingly, the GFAP-positive astrocyte
limitans border that formed the direct host interface with
nonionic DCHMO also extensively expressed galectin-3 and this
expression persisted chronically for at least 6 weeks (Fig. 4d, e;
Supplementary Fig. 8b).
These findings show that DCHMO evokes minimal levels of
fibrosis, whereas cationic DCHK evokes a stronger fibrotic FBR
with elevated levels of multiple matrix molecules at the interface
with preserved neural tissue. In addition, we identified a possible
conserved function for galectin-3 in isolating foreign bodies from
parenchymal neural tissue regardless of the severity of the FBR,
with its expression occurring rapidly following hydrogel injection
and present only in cells forming the material–tissue interface,
regardless of cell type (inflammatory cells, stromal cells, or
astrocytes). Galectin-3 is known to be associated with fibrosis and
wound healing in various tissue injuries including kidney, liver,
and heart44 and is significantly upregulated in macrophages/
microglia and reactive astrocytes after various traumatic CNS
injuries42,45–47. Here, we identify galectin-3 to also be an
important constituent of CNS FBRs to materials.
Tissue damage drives FBR and causes acute amyloid forma-
tion. We next looked for associations between FBR, inflamma-
tion, fibrosis and host tissue loss, and for other potential








Fig. 3 Different hydrogels attract inflammatory responses that differ in
intensity and cellular phenotype. a Detail images of differences in
inflammatory cell recruitment 1 week after injection of DCHMO, DCHK,
DCHMM hydrogels (G). b Detail images showing that CNS-derived P2RY12-
positive microglia do not migrate into non-neural tissue compartments in
spite of different FBRs evoked by DCHMO, DCHK, DCHMM. c Detail images
of hydrogel-tissue interface showing the escalating recruitment and
persistence of Ly6B2-positive neutrophils at cationic hydrogel surfaces at
1 week after injection. d Quantification of total Ly6B2 staining for hydrogels
1 week after injection. Not significant (NS) and **P= 0.0011 for CHIT and
DCHK versus DCHMM, respectively, one-way ANOVA with Bonferroni.
e Table summarizing the combination of antibodies used to identify
different inflammatory cell types. Graphs show mean ± s.e.m with individual
data points showing n= 5 mice per group.
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To do so, we first used mice expressing reporter protein trans-
genically targeted to host astrocytes via Aldh1l1-Cre-ERT2 and
evaluated host neural tissue damage and changes in various
molecular markers, including accumulation of amyloid precursor
protein (APP), a robust marker of axonal injury48 and one of its
breakdown products, beta-amyloid (Aβ)49. We compared repre-
sentative hydrogels displaying minimal or pronounced FBRs with
the CNS wound response to L-NIO stroke lesions at various
timepoints.
At 48 h after injection, DCHMO exhibited a minimal zone of
host neural tissue loss averaging only 25 µm, the equivalent of one
or two cells in thickness, whereas DCHK exhibited a significantly
greater, but still relatively small zone of host neural tissue loss of
~150 µm in thickness, as evidenced by: (i) astrocyte and neuron
loss but persistence of vasculature, (ii) presence and phagocytosis
of reporter protein debris, (iii) extravasation of blood-borne
fibronectin50, (iv) upregulation of CD13 expression along thin
PECAM-1-positive blood vessels within the damaged tissue zone,
and (v) infiltration of blood-borne phagocytic leukocytes (Fig. 5a,
b; Supplementary Fig. 9a–e).
Further characterization of the extent of axonal injury was
provided by APP staining. APP is low or undetectable by IHC in
healthy CNS tissue, but increases markedly after axonal
injury48,51. After 48 h, DCHMO displayed only small amounts of
APP accumulation at the hydrogel-host interface (Fig. 5c). In
contrast, APP was present throughout the narrow zone of neural
tissue damage induced by DCHK and APP accumulation was
prominent in damaged axon bundles close to DCHK deposits in a
manner comparable with L-NIO stroke lesions (Fig. 5c). By one
week, APP staining had decreased substantially and was
detectable only at the interface of neural to non-neural tissue,
and APP had returned to baseline at 6 weeks across all conditions
(Fig. 5c).
The formation of Aβ via cleavage of APP by β- and γ-secretase
enzymes is increasingly recognized as a normal occurrence during
CNS wound responses52,53. We evaluated the progression of APP
to Aβ (Fig. 5d). At 48 h, Aβ was sparse at the hydrogel-tissue
interface for both DCHMO and DCHK, whereas L-NIO stroke
lesions already showed clear Aβ accumulation at the borders of
infarcted and spared neural tissue (Fig. 5d). By one week, Aβ was
barely detectable around DCHMO and was comparable to PBS
injections where Aβ was constrained to the track of tissue
disrupted by the injection pipette (Supplementary Fig. 10a, b). At
1 week after DCHK, DCHMM injections and L-NIO stroke lesions,
Aβ accumulation was most prominent within the layers of CD13-
positive inflammatory cells that infiltrated areas of neural tissue
damage (Fig. 5d, e). In addition, in all conditions, there was
prominent colocalization of Aβ within Iba-1-positive reactive
microglia in adjacent spared neural tissue, suggesting phagocy-
tosis by these cells as well (Fig. 5e, Supplementary Fig. 10c).
Quantification confirmed significantly higher levels of Aβ at one
week for DCHK and DCHMM compared with DCHMO (Fig. 5e, f).
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Fig. 4 Hydrogels evoke fibrotic responses at the material–tissue interface
that can involve stromal or astroglial cells. a, b Detail images of stromal-
associated markers, collagen-1a1 (Col1a1), fibronectin, laminin, and galectin-
3 (Gal-3) and their relationship to non-neural CD13-positive cells at the
tissue interface of DCHMO a and DCHK b at 1 week after injection
(hydrogels, G). Colocalization of markers with CD13-positive cells is seen
as white staining. c Quantification of total Col1a1 and Gal-3 staining at
1 week after hydrogel injection. ***P= 0.0003 and =0.0002 for DCHMO
versus DCHK for Col1a1 and Gal-3 stromal markers, respectively, two-way
ANOVA with Bonferroni. Graphs show mean ± s.e.m with individual data
points showing n= 5 and 7 mice for DCHMO and DCHK, respectively. d
Detail image showing that adjacent to DCHMO, Gal-3 colocalizes with a
narrow band of GFAP-positive astrocytes that border the gel at 1 week. Gal-
3 and GFAP colocalization is seen as white staining. e, f Detail images
showing the temporal evolution of Gal-3 expression at the interface of
DCHMO e and DCHK f at acute (48 h, 48 h), subacute (1 week, 1wk) and
chronic (6 weeks, 6wk) timepoints after injection. Gal-3 and GFAP
colocalization is seen as yellow staining. Gal-3 and CD13 colocalization is
seen as white staining.
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compared with DCHK (Fig. 3c, d) was not associated with any
increase in Aβ formation (Fig. 5e, f), suggesting that Aβ is formed
as a result of acute neural tissue injury and not by ongoing
chronic inflammation. At 6 weeks, Aβ levels had reduced
markedly and were evident only within the persistent non-
neural tissue lesions for DCHK and L-NIO stroke (Fig. 5d).
These finds show that the inflammatory and fibrotic FBRs
evoked by cationic hydrogels were driven by narrow but
measurable zones of host neural tissue damage occurring along
hydrogel-host interfaces soon after injection and that this was
essentially absent with the nonionic DCHMO. These findings also
show that APP accumulation and Aβ formation around hydrogel
deposits occurred as a result of damage to neural tissue and
axonal injury. These observations are consistent with growing
evidence that APP accumulation and subsequent Aβ formation
are part of a conserved innate wound and FBR. Although the
specific functions of Aβ production in this context are not yet
defined, recent evidence suggests that Aβ may exert antimicrobial
activities52,53.
Astrocyte limitans borders isolate FBRs from neural tissue.
Neural tissue contains several types of glial cells that become
reactive around damaged CNS tissue and participate in FBRs.
Astrocytes are well known to form “scar borders” that serve as
limitans borders to isolate CNS lesions19. Microglia contribute to
border formation and exert phagocytic functions20, whereas oli-
godendrocyte progenitors (OPC) proliferate and repair myelin22.
We identified astrocytes and microglia by IHC for GFAP and
P2RY12, respectively, and OPC by staining for OLIG2 and the
reporter protein, td-Tomato (tdT), which had been transgenically
targeted by NG2(CSPG4)-Cre-ERT254. We compared combina-
tions of markers and probed blood–brain barrier (BBB) integrity
at 1 and 6 weeks after hydrogel injection or L-NIO stroke (Figs. 6
and 7).
GFAP-positive astrocytes had begun to form distinct borders
around all hydrogel deposits by 1 week after injections, and these
borders persisted and consolidated by 6 weeks. Astrocyte borders
around hydrogels were similar in appearance to borders formed
around L-NIO infarcts and clearly segregated persisting hydrogel
material and CD13-positive stromal and inflammatory cells from
neural tissue containing NeuN-positive neurons (Figs. 1c, d; 2a, b;
6a, b; 7a, b). Notably, astrocyte borders adjacent to DCHMO and
other nonionic hydrogels interfaced directly with gel surfaces with
limited intervening fibrosis or inflammation, whereas astrocyte
borders adjacent to DCHK and other cationic gels or L-NIO
interfaced with stromal and inflammatory cells (Figs. 2a, b, 4, 6a, b).
Astrocyte borders around hydrogels and L-NIO infarcts were
similar in appearance to astrocyte limitans borders that separate
healthy neural tissue from non-neural stromal cells along all
interfaces of normal CNS with meninges (Supplementary Fig. 1c)55.
Astrocyte border thickness at 6 weeks was proportionally greater
with increasing severity of FBR, such that DCHMO displayed the
thinnest astrocyte borders while DCHK and L-NIO both had similar
sized borders of more than double the thickness (Fig. 7e). Across all
conditions at 6 weeks, lateral astrocyte borders formed by gray
matter astrocytes, were thinner compared with medial borders that
recruited white matter astrocytes from the internal capsule (Figs. 1b,
7a, b, e).
Neural parenchyma extending from astrocyte borders exhib-
ited initially moderate astrocyte reactivity indicated by elevated
GFAP, which declined significantly over time and by 6 weeks was
minimal in all cases (Figs. 6a, b; 7a, b). Reactive microglia and
OPC intermingled with astrocytes along borders and adjacent
neural tissue, but did not infiltrate into hydrogels or contribute to
volumes of CD13-positive fibrosis and inflammation at any
timepoint examined (Fig. 6a–d and Supplementary Fig. 11a). At
6 weeks a thin, single cell layer of non-neural tissue (CD13-
positive) that expressed stromal cell markers PDGFRβ and
fibronectin interfaced directly with DCHMO and the astrocyte
limitans border (Supplementary Fig. 11b), whereas these cells
contributed to large volumes of non-neural fibrotic tissue in
DCHK and L-NIO strokes (Supplementary Fig. 11b, c).
Astrocyte border formation is essential for re-establishing BBB
integrity after CNS injuries30. To probe BBB integrity adjacent to
hydrogel deposits, we stained for mouse immunoglobulin (IgG)
and albumin, the two most abundant serum proteins30. As
expected, after 1 week and prior to border formation30, IgG, and
albumin staining were increased in neural parenchyma around
hydrogel injections and L-NIO stroke lesions, and were
significantly higher around DCHK, compared with DCHMO
(Fig. 6e, f; Supplementary Fig. 12a–c). By 6 weeks, serum protein
levels around DCHMO were indistinguishable from those in
uninjured tissue and were restricted to a thin layer of non-neural
tissue that interfaced with the astrocyte limitans border. In
contrast, around L-NIO stroke lesions and cationic DCHK, serum
proteins remained significantly elevated in neural tissue at 6 weeks
(Fig. 6e, f, Supplementary Fig. 12a–c).
These findings show that astrocytes rapidly form limitans
borders around hydrogels in a manner similar to borders formed
around ischemic or traumatic tissue damage, or that exist along
meningeal non-neural stromal tissue around healthy CNS.
Astrocytes, microglia, and OPCs become reactive in neural tissue
adjacent to hydrogel deposits or stroke lesions, but do not migrate
into the non-neural fibrotic tissue compartments that persist
chronically. Glial reactivity and BBB leakiness into neural tissue
adjacent to astrocyte borders persist longer adjacent to cationic
materials that generate substantial inflammation and fibrosis
compared with nonionic materials that do not.
FBR determines hydrogel resorption or persistence. To evaluate
the relationship between FBR and hydrogel resorption or per-
sistence, we compared nonionic DCHMO and cationic DCHK
deposits at various times after injection (Figs. 1 and 7). Quanti-
fication showed that after 48 h, DCHMO, and DCHK exhibited
deposits of similar size. After 1 week, DCHMO deposits had
decreased in size by 30%, but remained at this size after 6 weeks
and persisted essentially unchanged after 12 weeks (Fig. 7a–d, f).
In contrast, after 1 week DCHK deposits had decreased in size
significantly by over 50% and continued to steadily decrease in
size until there was no detectable deposit remaining at 6 weeks
(Fig. 7a, b, f). Over time, DCHMO exhibited no increase in CD13
levels above baseline, whereas DCHK evoked a steadily increasing
infiltration of CD13-positive inflammatory and stromal cells that
proceeded in a concentric fashion from hydrogel-tissue interfaces
inwards until the entire deposit was consumed (Figs. 1c, d, 3a, 4b,
7a, b, g; Supplementary Fig. 7a). By comparison, the wound
response to L-NIO-induced ischemia attracted a pronounced
infiltration of CD13-positive cells that rapidly filled the entire
volume of damaged tissue and then persisted (Figs. 1c, d, 7a, b).
These findings show that DCHMO and other nonionic
hydrogels persist and are not efficiently resorbed in vivo because
they do not attract sufficient CD13-positive phagocytes. In
contrast, DCHK and other cationic hydrogels attract these
phagocytic leukocytes to their interfaces with host tissue and
are gradually resorbed from the outside in and become replaced
by fibrosis. DCHMM was an exception to this general cationic
hydrogel resorption trend and instead showed minimal hydrogel
resorption after 3 weeks (Supplementary Fig. 7c). This chronic
hydrogel persistence coupled with the unresolved Lys6B2-positive
neutrophils at the material–tissue interface suggests that DCHMM
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is unable to be readily cleared due to frustrated phagocytosis,
possibly owing to toxicity towards or repulsion of phagocytosing
cells. Thus, hydrogel properties determine FBR features, which in
turn determine hydrogel resorption or persistence.
Microparticles alter FBR and hydrogel resorption. Incorporat-
ing nano/microparticles (MPs) into hydrogels may be a useful
tool to enhance the control of delivery of multiple and diverse
molecular cargos independently from a single construct to the
CNS18,56,57. As introduction of particles may alter the physio-
chemical properties of hydrogels into which they are loaded, we
examined the effects on FBR and resorption of hydrogels laden
with polyethylene glycol (PEG)-based nonionic MP formulated
via a standard inverse emulsion thiol-ene Michael addition
process (Fig. 7h)58–60. MP, with an average diameter of 3.3 µm,
imparted a modest increase in mechanical properties to DCH but
did not alter injectability (Supplementary Fig. 13a–f). MP at high
concentrations were non-toxic to neural progenitor cells in vitro
(Supplementary Fig. 13d). As described above, nonionic DCHMO
and HAMC on their own evoked minimal fibrotic or inflam-
matory responses and formed long persisting deposits. Addition
of nonionic MP to these hydrogels caused pronounced recruit-
ment of peripheral inflammatory cell infiltration in the form of
both CD13-positive macrophages and Lys6B2-positive neu-
trophils, as well as rapid hydrogel resorption and fibrotic repla-
cement (Fig. 7i–k; Supplementary Fig. 13g–k). Nevertheless, the
FBR of MP loaded DCHMO did not detectably increase acute
neural tissue loss or axonal injury (Supplementary Fig. 13g, h).
Similar sized non-toxic MP as the ones evaluated here (~3 µm
diameter) have previously demonstrated a high susceptibility to
phagocytosis in vitro by macrophages61. Incorporating MP into
nonionic hydrogels may stimulate similar size recognition pro-
grams in vivo thus leading to the recruitment of phagocytes by
mechanisms other than those associated with host neural tissue
damage at the hydrogel-host interface as was the case for cationic
hydrogels. These findings show that adding such MP to hydrogels
that would otherwise be ignored by phagocytes can induce a
phagocytic FBR that steadily resorbs the material and replaces it
with fibrosis.
FBR alters hydrogel molecular delivery to CNS parenchyma. To
characterize FBR effects on delivery of molecular cargos, we first
examined the biodistribution of model non-bioactive molecules
released into neural tissue adjacent to hydrogel deposits, and
second evaluated the efficacy of bioactive growth factor delivery.
As non-bioactive molecules, we used biotinylated dextran amines
(BDA) of different molecular weights because they are non-
immunogenic, fixable, easily detected by IHC, and because 10
kDa (BDA-10) and 70 kDa (BDA-70) BDAs exhibit hydro-
dynamic radii that approximate bioactive protein growth factors
and therapeutic monoclonal antibodies, respectively62,63.
BDAs injected in PBS are well documented to diffuse locally
throughout CNS neural parenchyma and along perivascular
spaces, and are taken up by neurons as well as by microglial and
perivascular phagocytic cells in a size dependent manner64. A
detailed comparison of the biodistributions of BDA-10 and BDA-
Fig. 5 Hydrogel FBR severity is determined by the extent of acute neural
tissue damage at the material interface, which is associated with axonal
damage, APP accumulation, and amyloid formation. a Detail images of the
material–tissue interface for DCHMO and DCHK at 48 h after injection.
ALDH1L1-tdT reporter and GFAP identify host astrocytes and the loss of
these cells demarcates regions of host tissue damage. At 48 h, CD13-
positive cells in this damaged tissue region predominately label actively
remodeling vasculature. b Quantification of radial thickness of tissue
damage around DCHMO and DCHK (n= 9 mice per group). ***P= 0.0001
Welch’s (unequal variance) two-tailed t test (t= 6.56, df= 8.74).
c, d Detail images for DCHMO, DCHK, and L-NIO-induced stroke at acute
(48 h, 48 h), subacute (1 week, 1wk), and chronic (6 weeks, 6wk)
timepoints after injection, comparing staining for amyloid precursor protein
(APP) c or amyloid-beta (Aβ) d with GFAP and CD13. e Images show Aβ,
Iba-1, and CD13 at the interface of DCHMO, DCHK, and DCHMM with host
tissue at 1 week after injection. f Quantification of Aβ at 1 week after
DCHMO, DCHK and DCHMM. NS or *P= 0.0153 and =0.0227 for DCHMO
versus DCHK and DCHMM, respectively, one-way ANOVA with Bonferroni,
n= 4 mice per group. All graphs shows mean ± s.e.m with individual data
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70 released from PBS, DCHMO, or DCHK is presented in
Supplementary Figs. 14–16. In brief, under all conditions, BDAs
were detectable only in the ipsilateral hemisphere. Notably,
delivery of BDAs of either size via DCHMO or DCHK resulted in
significant differences both in the depth of penetration of BDAs
into neural tissue and in cellular uptake such that BDAs of either
size released from DCHMO were found to be more concentrated
locally near hydrogel deposits, whereas BDAs released from
DCHK showed increased radial diffusion (Supplementary
Figs. 14–16), (Supplementary Fig. 16). BDAs of different sizes
showed dissimilar cellular uptake profiles such that BDA-70 was
consumed preferentially by phagocytes in neural tissue while
BDA-10 showed enhanced neuron uptake. Nevertheless, the
hydrogel used for delivery also had substantial effects on cellular
uptake of each BDA (Supplementary Fig. 16). BDA-70 showed
low but clearly detectable uptake by neurons when released from
DCHMO but no neuron uptake when released from DCHK. BDA-
10 released from DCHMO showed extensive uptake by neurons as
well as axon labeling throughout the adjacent neuropil and low
accumulation in phagocytes. By contrast, BDA-10 released from
DCHK showed low uptake by neurons, no obvious axon labeling
and pronounced uptake by phagocytes (Supplementary Figure
16). These differences may relate to the increased activation and
number of microglia in neural tissue adjacent to DCHK deposits,
which could either stochastically or actively favor greater uptake
of BDA-10 by phagocytes over neurons. These findings indicate
that hydrogels with different FBRs exhibit differences not only in
the distribution of molecular delivery into neural tissue, but also
in the type of cells that may be primarily targeted.
We therefore next compared the biodistribution of BDA-10
released from different hydrogels that displayed escalating and
unique severities of FBR: DCHMO, DCHK, DCHMM, and CHIT
(Fig. 8a). We quantified the proportion of BDA present in the
non-neural compartment defined as the area of hydrogel deposit
and its non-neural surrounding tissue, versus the neural
compartment defined as the neural tissue surrounding the
deposits containing viable neurons and different neuroglia
(Fig. 8b–d, Supplementary Fig. 17). At 2 weeks after injection,
DCHMO, with the least noxious FBR showed the highest total
delivery of BDA into the neural compartment, and yielded greater
uptake in neurons, which was highest local to the hydrogel-tissue
interface (Fig. 8b–d). DCHK exhibited less neural parenchyma
delivery than DCHMO but more than DCHMM and CHIT, and
BDA was preferentially taken up by microglia rather than
neurons (Fig. 8e, f). DCHMM and CHIT, which show the most
severe FBR (Fig. 3b, d), displayed: (i) significantly increased
accumulation of BDA in non-neural compartments associated
with the FBR (Fig. 8b); (ii) reduced uptake of BDA by local
neurons (Fig. 8c); and (iii) greater BDA accumulation in
macrophages (CD13-positive/CD68-positive cells) (Fig. 8e).
Notably, DCHK, DCHMM and CHIT exhibited pronounced BBB
leakage with extended distribution of serum albumin through
neural parenchyma compared with DCHMO (Supplementary
Fig. 17c, d) and degree of BBB leak correlated with increased BDA
biodistribution throughout the brain and increased inflammatory
cell phagocytosis of BDA (Fig. 8d, e, Supplementary Fig. 17a).
Serum proteins such as albumin bind systemically delivered
biological materials such as bioactive proteins, small molecule
drugs and nanoparticles, and alter their biodistribution65. In
addition, serum proteins are proinflammatory in neural
tissue19,22. We also evaluated the biodistribution of BDA-10
released from MP that had been loaded into DCHMO. The
increased non-neural and phagocyte dominated FBR associated
with MP inclusion into nonionic DCHMO correlated with
significantly decreased BDA-10 accumulation in neural tissue at
1 week and extensive consumption of BDA-10 by CD13-positive
cells (Supplementary Fig. 18). Together, these data show that
hydrogels with pronounced non-neural FBRs have reduced
molecular delivery efficacy to neural tissue and that this reduction












Fig. 6 Astrocytes form limitans borders that isolate hydrogels and non-
neural FBR components from viable neural tissue. a, b Progression of
astrocyte limitans border formation from 1 week a to 6 weeks b for DCHMO,
DCHK, and L-NIO-induced stroke. c, d OPC identified by NG2-targeted
reporter (tdT) c and Olig2 d intermingle with GFAP-positive astrocytes and
do not migrate into CD13-positive regions. e Comparison of extent of
blood–brain barrier (BBB) disruption and repair as measured by IgG staining
around DCHMO and DCHK deposits at 1 and 6 weeks after injection. f
Quantification of the percentage increase in IgG levels in the hydrogel
injected caudate putamen (CP) normalized to the non-injected contralateral
side. **P= 0.0012 and ***P= 0.0001 for DCHK versus DCHMO at 1 week
and 6 week, respectively, and not significant (NS) for DCHK samples
between the two timepoints, two-way ANOVA with Bonferroni. Graph
shows mean ± s.e.m with individual data points superimposed showing n=
5 and 6 mice for DCHMO and DCHK, respectively.
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At last, we evaluated the effect of FBR on hydrogel-mediated
delivery of bioactive molecules in vivo. Basal forebrain cholinergic
neurons are exquisitely sensitive to nerve growth factor (NGF)
levels and atrophy when deprived of NGF and hypertrophy when
exposed to exogenous NGF (Fig. 8g)34,66,67. To compare the
efficacy of NGF delivery by various hydrogels, we quantified the
size of local striatal cholinergic neurons. NGF delivered from
DCHMO and DCHK stimulated significant 40% increases in
ipsilateral cholinergic neuron size relative to uninjected controls,
whereas NGF delivered from DCHMM and CHIT, which attract a
severe non-neural FBR, showed highly variable effects with no
overall significant increase (Fig. 8h). Incorporating data from
across the molecular delivery and FBR phenotype characteriza-
tions into a principal component analysis (PCA) showed a
significant inverse correlation between neural tissue molecular
delivery efficacy and the severity and intensity of hydrogel FBR-
associated inflammation (Fig. 8i, j, Supplementary Fig. 19).
These findings show that delivery of molecular cargo from
hydrogels to CNS tissue is influenced by the nature and severity
of the material-evoked FBR. In particular, an increased recruit-
ment of peripherally derived phagocytes into hydrogel deposits
results in increased consumption of cargo molecules and reduced
neural tissue delivery. Further, a minimal hydrogel FBR with little
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proportion of targeting of cargo molecules to neurons. In
contrast, more severe FBRs with pronounced BBB leakage
contributes to increased dispersal of delivered molecules
throughout larger volumes of neural parenchyma, and to greater
targeting of those molecules to phagocytosis by microglia and
perivascular cells.
FBR alters hydrogel molecular delivery and wound healing in
CNS stroke injury. Injectable hydrogels are being tested exten-
sively to deliver drugs, including growth factors, to CNS injuries.
The influence of hydrogel FBRs in determining effectiveness of
such treatments on neural repair outcomes remains largely
uncharacterized. Unfavorable FBR effects may mask or dilute the
efficacy of treatments delivered by hydrogels. To determine
hydrogel FBR effects on molecular delivery to CNS injuries we
injected hydrogels loaded with NGF into mouse CP at 48 h after
initiating a large focal stroke lesion via a 2 µL injection of L-NIO
(Fig. 9a). We evaluated local striatal cholinergic neuron survival
and size, as well as neuropil changes, as measures of NGF-
responsiveness at one week after hydrogel injections into stroke
lesions (Fig. 9b, c). NGF delivery from all hydrogels stimulated a
significant and ~50% increase in size of surviving, ipsilateral
ChAT-positive neurons compared with untreated L-NIO only
(Fig. 9d). NGF delivered from DCHMO but not DCHK or
DCHMM also stimulated a small but significant increase in the
size of contralateral ChAT-positive neurons (Fig. 9d). L-NIO
stroke injury triggered a significant loss of ChAT-positive neu-
rons in the ipsilateral striatum; and NGF delivered from DCHMO,
but not from DCHK or DCHMM, rescued the number of ChAT-
positive neurons such that they were comparable to uninjured
contralateral striatum (Fig. 9e). To investigate effects of NGF
delivery on density of cholinergic axon networks we assessed
ChAT staining intensity averaged across the neuropil. NGF
delivered from DCHMO but not DCHK or DCHMM stimulated an
increase in the mean ChAT intensity in the ipsilateral neuropil
compared to the untreated stroke (Fig. 9f). Applying a PCA that
combined all ChAT related parameters for individual animals
showed a dominant PC1 that described 73.70% of total variation
across the cohort (Fig. 9g). PC1 results for different hydrogels
showed a remarkably similar hydrogel efficacy correlation to that
seen for NGF delivery to uninjured healthy striatum. Animals
treated with NGF using DCHMO showed the most effective NGF
delivery outcomes, observed as higher positive PC1 values
(Fig. 9g). DCHK displayed significantly reduced delivery efficacy
compared to DCHMO but still provided benefits over the
untreated L-NIO only cohort. Delivery via DCHMM failed to
significantly alter outcome compared with untreated stroke.
The natural wound healing response stimulated following
stroke may be altered by hydrogel FBRs. To characterize the
perturbation of the sterile inflammatory response after stroke
caused by hydrogel FBRs, we used CD13 to identify non-neural
cells, GFAP to define the astrocyte border and neurofilament
(NFM) to demarcate neural tissue (Fig. 9h, i). In untreated
strokes, distinct lesion compartmentalization was observed as
described earlier with CD13-positive cells separated from NFM-
positive tissue by discrete GFAP-positive astrocyte borders.
Wound healing progression, defined by the distribution and
total numbers of CD13-positive cells in lesion cores, was
unaltered by the injection of DCHMO (Fig. 9j, k). By contrast,
depots of both DCHK and DCHMM substantially modified the
lesion by reducing the total number of total CD13 cells in the
lesion core and stimulating a renewed increase in infiltration and
persistence of CD13-negative, DAPI-positive inflammatory cells,
likely neutrophils, into this tissue volume. Surrounding the non-
neural lesion core, DCHMO caused no significant increase in
baseline CD13 compared with the L-NIO only control. By
contrast, the two cationic materials, DCHK and DCHMM,
stimulated significant increases in CD13-positive cell infiltrates
that formed rims around the entire host interface of material
deposits that persisted immediately adjacent to lesion cores at
1 week (Fig. 9l). These cationic materials also caused additional
damage to ipsilateral neuropil beyond that attributed to the
stroke, whereas no significant increase in neuropil loss was
detected for DCHMO (Fig. 9m).
These data show that effectiveness of molecular delivery from
hydrogels in stroke lesions is governed by FBR severity in a
manner similar to observations in uninjured tissue. Notably,
introduction into stroke lesions of hydrogels that evoked FBRs of
increasing severities caused escalating destruction not only of
neural tissue beyond focal lesion cores but also extensive
destruction of peripherally derived cells that infiltrate into lesion
cores to initiate wound healing (Fig. 9h–m). This effective re-
injuring of CNS lesions caused by hydrogels with severe FBRs
may prolong the duration of acute inflammation, prevent re-
establishment of BBB and leave the recipient with increased
susceptibility to infection and further neural tissue damage thus
potentially negating therapeutic effects derived from local
molecular delivery.
Discussion
Here, we show that CNS FBRs to biomaterials mimic CNS wound
responses and exist on a severity spectrum that is determined by
definable chemical functionalities perceived by the host tissue at
the biomaterial-tissue interface. Moreover, the nature and severity
Fig. 7 Hydrogel FBR with recruited CD13-positive cells leads to hydrogel resorption. a, b Survey and detail images show qualitative reductions in size of
DCHK deposit and L-NIO-induced infarct, but not of DCHMO deposit at 6 weeks after injection c, d. Survey and detail images show DCHMO deposit remains
unresorbed up to 12 weeks after injection. e Quantification of GFAP-positive cell border thickness at lateral (gray matter) or medial (internal capsule)
borders at 6 weeks. *P= 0.0469 and **P= 0.0021 (lateral), = 0.0012 (medial), and ***P= 0.0001 versus DCHMO on same side; not significant (NS)
between DCHMO on either side, **P= 0.0012 for border location effect across all samples, two-way ANOVA with Tukey (n= 5, 4, 4 mice for DCHMO,
DCHK, and L-NIO, respectively). f Quantification of change in hydrogel radius for DCHMO and DCHK from 2 to 42 days. NS, ***P= 0.0001 and ***P <
0.0001 for DCHK versus DCHMO at 7 and 42 days, respectively; NS for DCHMO at 7 versus 42 days and for DCHMO versus DCHK at 2 days, two-way
ANOVA with Bonferroni. g Quantification of change in total CD13 for DCHMO and DCHK from 2 to 42 days. **P= 0.0067 and ***P < 0.0001 for DCHK
versus DCHMO at the same timepoints. NS between the various timepoints for DCHMO, two-way ANOVA with Bonferroni. For both f and g, n= 9, 10, 5
mice for DCHMO at 2, 7, and 42 days; n= 9, 12, 5, 4 mice for DCHK at 2, 7, 21, 42 days. h Schematic of microgel particle (MP) synthesis involving inverse
emulsion of polyethylene glycol (PEG)-based thiol and acrylate functionalized oligomers that react via Michael addition. MP can be readily suspended in
hydrogels. i, j Survey images of FBR to DCHMO loaded with MP at 1 week and 6 weeks show that incorporation of MP into DCHMO leads to recruitment of
CD13-positive cells and hydrogel resorption. k Quantification of effect of incorporation of MP(+) on total CD13-positive cell response for DCHMO and
DCHK at 1 week. NS and ***P < 0.0001, two-way ANOVA with Bonferroni, n= 10, 6, 12, and 9 mice for DCHMO, DCHMO+MP, DCHK and DCHK+MP,
respectively. All graphs show mean ± s.e.m with superimposed individual data points.
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Fig. 8 Hydrogel FBR alters CNS molecular delivery. a Detail images of BDA (10 kDa) biodistribution released from DCHMO, DCHK, DCHMM, and CHIT at
2 weeks. b Quantification of BDA in tissue compartments adjacent to hydrogels. ***P < 0.0001 versus DCHMO; not significant (NS) for DCHMM versus
CHIT c Quantification of the normalized number of BDA-positive neurons at 2 weeks. *P= 0.0375 (DCHMM) and = 0.0413 (CHIT) and NS (DCHK) versus
DCHMO. d Quantification of the radial distance to the 50% percentile BDA-positive neuron from the hydrogel-tissue interface. ***P < 0.0001 versus
DCHMO. e Quantification of BDA-positive inflammatory cells at 2 weeks. *P= 0.0036, **P= 0.0005 (CD13),= 0.0008 (CD68), ***P < 0.0001 versus
DCHMO. *P= 0.0074 (CD13), = 0.003 (CD13+ CD68) and ***P < 0.0001 (CD68) for DCHK versus DCHMM. For all graphs in b–e, n= 6 mice per group. f
Detail images showing phenotype of BDA-positive cells adjacent to hydrogel deposits. g Detail images showing increase in cholinergic (ChAT-positive)
neuron size in striatum by NGF delivered from DCHMO. h Quantification of increase in cholinergic neuron size normalized to contralateral side at 1 week
after injection of 1 µL NGF (1 µg/µl) releasing hydrogels. ***P < 0.0001 and **P= 0.0054 (DCHMM) and = 0.0029 (CHIT) versus DCHMO, NS for DCHMM,
and CHIT versus untreated, *P= 0.0429 for DCHMM and = 0.0233 for CHIT versus DCHK respectively, NS between DCHMO and DCHK (n= 5, 6, 5, 5, and
6 mice for DCHMO, DCHK, DCHMM, CHIT, and untreated, respectively). i Principal component Analysis (PCA) for DCHMO, DCHK, DCHMM, and CHIT
hydrogels incorporating data from molecular delivery and immunohistochemistry evaluations. j Graphical representation of the positions of hydrogels along
PC1 axis (accounting for 64.22% of total variance) with the positive direction representing effective neural molecular delivery while the negative direction
represents molecular delivery to inflammatory cells, ***P < 0.0001 for all versus DCHMO, ***P= 0.0007 for DCHK versus DCHMM and ***P < 0.0001 for
DCHK versus CHIT, NS for DCHMM versus CHIT (n= 6 mice per group). For all graphs, data are mean ± s.e.m. Statistical analysis using one (c, d, h, j) or
two-way (b, e) ANOVA with Bonferroni.
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Fig. 9 Hydrogel FBR alters molecular delivery of NGF and wound healing in CNS stroke injury. a Schematic summarizing experimental paradigm. b, c
Images showing cholinergic (ChAT-positive) neurons in striatal stroke at 1 week after hydrogel (G) injection. d Quantification of mean cholinergic neuron
size ipsilateral and contralateral to stroke and hydrogel injection. ***P < 0.0001 for hydrogels versus L-NIO only and not significant (NS) between hydrogels
ipsilaterally, *P= 0.0179 (L-NIO), = 0.0317 (DCHK) and = 0.004 (DCHMM) versus DCHMO contralaterally. e Quantification of cholinergic neuron number
in striatum ipsilateral and contralateral to stroke and hydrogel injection at 1 week. *P= 0.0192, **P= 0.0027, ***P= 0.0002 versus DCHMO ipsilaterally,
NS between all samples in contralateral striatum. f Quantification of mean ChAT intensity in neuropil ipsilateral and contralateral to stroke and hydrogel
injection, *P= 0.0442 (DCHK), = 0.0203 (DCHMM), ***P < 0.0001 (L-NIO) versus DCHMO ipsilaterally, NS between all samples in contralateral striatum.
g PC1 score for L-NIO only and hydrogels for PCA comparing all ChAT-neuron parameters. Positive direction represents increased ChAT responsiveness to
NGF delivery, ***P < 0.0001, **P= 0.0011, NS versus L-NIO only, *P= 0.0404 and ***P= 0.0004 for DCHK and DCHMM versus DCHMO, respectively. h, i
Images showing altered phenotypes of CD13-positive lesion cores (LC), astrocyte border, and preserved neural tissue of striatal strokes at 1 week after
hydrogel injections. j CD13-positive cell intensity plots measured radially from the center of the stroke lesion. Data are mean ± s.e.m, with s.e.m.
represented as light shaded banded areas. Location of astrocyte (GFAP) border is maximum of mean GFAP intensity plot for L-NIO only. The integral of
plot to left and right of GFAP border is total CD13 in lesion and hydrogel FBR respectively. k, l Quantification of total CD13-positive cells in lesion k and FBR
l, NS, and ***P < 0.0001 versus L-NIO only, *P= 0.0173 for DCHMO versus DCHK. Baseline in l. is mean total CD13 in L-NIO only. m Quantification of
percentage neuropil remaining following stroke and hydrogel treatment in immunohistochemistry sections at center of lesion, ***P < 0.0001, *P= 0.0385
and NS versus L-NIO only. For all graphs, data are mean ± s.e.m. with superimposed individual data points showing n= 8 mice per group. Statistical
analysis using one (g, k, l, m) or two-way d–f ANOVA with Bonferroni.
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of FBRs significantly affect multiple aspects of biomaterial func-
tion when applied to both healthy and ischemic stroke injured
neural tissue. These findings have broad implications for devel-
oping, testing, and using biomaterials for CNS applications, and
also for understanding the conserved biology of the CNS wound
response and astroglial limitans border formation. We provide a
framework for comprehensively evaluating in vivo responses to
biomaterials for CNS applications, which may facilitate the
development and characterization of new and improved systems.
As a platform to study CNS FBRs evoked by definable chemical
functionalities presented to host cells by biomaterials, we used
readily modified synthetic hydrogels whose direct interfaces with
host cells can sensitively and intimately be evaluated in vivo. Our
findings show that specific physiochemical properties presented
at biomaterial–host interfaces, such as cationic, nonionic, or
anionic interfaces with CNS cells, evoke quantifiably different
FBR phenotypes with respect to levels of stromal cell infiltration,
inflammation, tissue fibrosis, astroglial border formation, and
BBB disruption. Moreover, we show that FBRs evoked by mate-
rials in CNS are directly related to, and mimic, the multicellular
CNS wound response to tissue injury (modeled here by the
response to an ischemic infarct), and are best understood in the
context of this conserved biology. Trauma, ischemia, auto-
immune attack and infections all generate potentially toxic cel-
lular debris that trigger multicellular wound responses as
naturally occurring events. The conserved CNS wound response
serves to recruit inflammatory cells that degrade toxic elements
and also simultaneously serves to isolate damaged tissue, debris,
and inflammation from adjacent viable neural tissue and to
restore barrier functions important for normal CNS
function19,22,55. In this manner, naturally occurring CNS wound
responses give rise to discrete lesion compartments with central
cores of non-neural tissue surrounded by astrocyte limitans
borders that are continuous with spared and reorganizing neural
tissue. This compartmentalized organization is mimicked by
FBRs evoked by biomaterials (Fig. 10). This specialized multi-
cellular and compartmentalized CNS wound response or FBR is
not present in peripheral tissues, and thus evaluation of bioma-
terial FBR in peripheral tissue alone is not sufficient to predict
performance in the CNS. Naturally occurring CNS wound
responses exist on a severity spectrum that varies with: (i) the
degree of the tissue damage, (ii) the nature and the toxicity of
debris, and (iii) the presence or absence of microbes or their
associated signals. Similarly, the nature and severity of FBRs to
biomaterials vary with the molecular features of the interface
presented to host tissue.
The phenotypic differences in FBRs for different hydrogels
mimic the diversity of functional barriers that are established in
various healthy and disease states in the CNS (Fig. 10). FBRs
evoked by nonionic and anionic interfaces, such as seen for
DCHMO, are minimal and appear morphologically similar to
healthy glia limitans borders that exist at natural edges of healthy
CNS tissue such as the meninges. These discrete glia limitans
borders are formed at the new discontinuity in neural tissue that
is created as a result of the injection of these material into healthy
neuropil. Using dynamic and biologically conserved processes,
CNS glia form borders around all entities detected as being of
“non-neural” origin, including stromal cells, microbial organisms
or biomaterials. Therefore, neural integration with biomaterial
constructs, even those displaying a minimal FBR, will require
identifying strategies to regulate or disrupt the processes by which
glia recognize the need to form these borders. FBRs to cationic
materials, such as DCHK, that attract and allow resorption by
innate-immune cells, exhibit the most striking similarity to stroke
lesions. As the focal injury zone created by these materials is less
diffuse than stroke lesions and isolated to only a few cell layers
adjacent to the material interface, these materials may provide a
useful tool for evaluating the biology of cellular processes
involved in CNS injury lesion border formation. In contrast,
another cationic material, DCHMM, which is incapable of being
resorbed by innate-immune cells due to frustrated phagocytosis,
displays characteristic concentric inflammatory cell layers that are
phenotypically similar to chronic granuloma caused for example
by mycobacterial infections. This material may prove a useful tool
for studying granuloma pathophysiology. The spectrum of bio-
material FBRs identified in this study mimic various aspects of
CNS pathology and may each individually prove to be useful tools
to controllably elucidate, and thus further dissect, the cellular
mechanisms involved in natural host responses to CNS injury
and disease.
Our findings also emphasize the need for use of multiple
markers to assess multiple FBR dimensions, including markers of
stromal, inflammatory and multiple glial cells, as well as markers
of neural tissue damage and fibrosis. We show that GFAP, a
commonly used marker of astrocyte reactivity that can indicate
tissue pathology19, is on its own not a sufficient or reliable marker
to evaluate and differentiate material or device FBRs. For exam-
ple, we show that total GFAP levels are essentially indis-
tinguishable in neural tissue within close proximity to
biomaterials that evoke markedly different FBR severities,
including FBRs that evoke pronounced levels of inflammation
and fibrosis that impact significantly on function. Our findings
provide a framework of multiple molecular markers and experi-
mental tools for comprehensive evaluation of material FBRs in
the CNS in vivo using readily available immunohistochemical
reagents that can be applied to benchmark the performance of
new biomaterial formulations against various well characterized
formulations used here. Future work to extend the FBR evalua-
tion framework could include dynamic physiological evaluations
of neurons and glia in the preserved neuropil adjacent to bio-
material FBRs by incorporating emerging neurobiology techni-
ques such as non-invasive in vivo imaging of single wavelength
molecular sensors68,69.
We also show that the nature and severity of FBRs strongly
influence biomaterial function in the CNS as studied here in the
form of rate of hydrogel resorption, biodistribution of molecular
cargo delivery to neural parenchyma and efficacy of bioactive
molecular delivery. Thus, developing hydrogels and other bio-
materials with efficient functions for CNS applications will
require a detailed understanding of their in vivo FBRs. In vitro
evaluations of molecular release dynamics are on their own
insufficient to predict efficacy of molecular delivery in the CNS
in vivo, because delivery will be strongly influenced by CNS-
specific FBRs. For example, we show that MPs that significantly
extend molecular release duration from hydrogels in vitro can
attract phagocytes in vivo that significantly reduce molecular
delivery compared with the hydrogels they are suspended in.
Notably, our findings indicate that hydrogel formulations with
features that attract phagocytic cells such as blood-borne mac-
rophages and neutrophils will have particularly poor functional
performance in molecular delivery to host tissue (and most likely
also as vehicles for cell grafts). Moreover, we show that these
hydrogel features may not be revealed by solely examining the
glial response of more distant surrounding neural tissue, because
hydrogel deposits are rapidly and effectively isolated as part of the
FBR, which mimics naturally occurring wound responses that
maximize the protection of adjacent neural tissue19,22. This study
further demonstrated that materials that elicited severe FBRs
when applied to healthy, uninjured brain lead to worse bioactive
molecular delivery and impeded natural wound repair processes
when applied to stroke lesions. Therefore, evaluating biomaterial
FBRs in uninjured, healthy CNS represents important and
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necessary in vivo investigations for any new material prior to
consideration for use to deliver experimental therapies to pre-
clinical CNS injury models.
In this study, we used hydrogels as surrogate biomaterials to
characterize host responses to specifically presented chemical
functionalities, and molecular delivery from hydrogels was the
primary functional outcome measure evaluated. The basic prin-
ciples we identified can inform the development of materials for a
variety of CNS applications including implantable neuro-
prostheses for recording and stimulating neural circuit
activity2,3,23,70. For example, we show that surface charge at the
material–host interface influences the severity of FBRs, which in
turn will influence the degree of protective fibrotic and astrocyte
barrier formation, which serves to isolate the materials from
adjacent neural tissue and may thereby attenuate function. Thus,
such devices will also benefit from detailed characterization of
FBRs as described here. Although the bulk of implantable neu-
roprostheses most frequently employed in human and non-
human primate studies currently make use of non-resorbable,
hydrophobic polymers that may stimulate unique FBR pheno-
types in addition to that described here23, emerging systems are
opting for hydrophilic, hydrogel-based coatings/substrates with
comparable chemistries to this study71,72. Thus, it would seem
particularly appropriate to apply the FBR evaluation framework
outlined here to these new formulations as part of preclinical
testing protocols moving forward. Furthermore, incorporating the
identified hydrogel chemical functionalities that evoked minimal
FBRs (e.g., methionine sulfoxide functional groups from
DCHMO) into future neural electrode design may be a useful
strategy in attenuating the thickness of disrupted tissue and the
intensity of the astroglial border-forming response between the
device and viable neural tissue.
Our findings also inform the understanding of CNS wound
responses by demonstrating and characterizing how FBRs fall
firmly within the framework of the conserved multicellular biology
of such responses. In this regard, we also add to the growing evi-
dence48–53 that APP accumulation and the acute formation of Aβ
are consequent responses to neural tissue injury that occur in direct
proportion to the level of neuronal and axonal damage, and are thus
part of the conserved biology of CNS wound responses and FBRs.
In conclusion, we show that material FBRs are determined by
definable properties presented at host interfaces, which can be




































Fig. 10 Schematic summarizing the main findings of this study. a FBRs to hydrogels injected into healthy uninjured CNS mimic natural wound healing
responses to CNS tissue injury and exist on a severity spectrum that is dependent on definable material properties. This study identified that hydrogel
chemistry presented to the host at the biomaterial-tissue interface determines FBRs and that CNS FBR phenotype and its severity alters hydrogel function
in terms of molecular delivery and biomaterial resorption. (i) Non-ionic and anionic hydrogels demonstrated: minimal peripheral derived inflammation,
minimal fibrosis, limited resorption, and enhanced molecular delivery to neurons. Cationic hydrogels provoke significant non-neural tissue (NNT) FBRs
resulting in predominant inflammatory cell delivery as well as either rapid resorption (ii), or frustrated phagocytosis and persistent acute inflammation and
limited resorption (iii). b FBRs to hydrogels injected into subacute CNS stroke injuries influenced molecular delivery to preserved neurons and altered CNS
wound healing processes. When applied to striatal stroke, nonionic hydrogels [DCHMO–(i)] showed improved bioactive molecular delivery to neurons
without significantly altering the stroke lesion core (LC). Cationic materials [DCHK–(ii) and DCHMM–(iii)] showed reduced molecular delivery efficacy and
disruption of natural wound healing processes within LCs.
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modified to minimize or evoke specific responses. Understanding
these properties and the CNS-specific FBRs that they evoke
in vivo will be critical to designing new materials for diverse CNS
applications. In addition, this observation raises the intriguing
prospect of engineering biomaterials with originally inert profiles,
which can then be modified to present specific molecular features
in order to dissect cell surface and contact-mediated molecular
mechanisms that drive specific elements of naturally occurring
CNS wound responses.
Methods
Animals. All in vivo experiments involving the use of mice were conducted
according to protocols approved by the Animal Research Committee (ARC) of the
Office for Protection of Research Subjects at University of California Los Angeles
(UCLA). All in vivo animal experiments were conducted within approved UCLA
facilities using wildtype or transgenic C57/BL6 female and male mice that were
aged between 8 weeks and 4 months old at the time of craniotomy surgery.
Transgenic td-Tomato (tdT) reporter mice were bred with inducible Cre lines to
identify Astrocytes (Aldh1L1-Cre-ERT2) and NG2 cells (NG2-Cre-ERT2).
Transgenic mice (aged between 6 and 12 weeks) were administered tamoxifen to
induce Cre expression. Tamoxifen in corn oil at a concentration of 20 mg/ml was
administered via intraperitoneal (IP) injection for 5 days at a dose of 50 mg/kg
per day. Following the last dose of tamoxifen, mice were kept for 3 weeks before
undergoing surgery for hydrogel injection to allow residue tamoxifen to clear out of
the mouse’s system. Mice were housed in a 12-hour light/dark cycle in a specific
pathogen-free facility with controlled temperature (maintained within range of
20–26 °C) and humidity (maintained within range of 30–70%) and were provided
with food and water ad libitum.
Surgical procedures for mice. All surgical procedures were approved by the
UCLA ARC and conducted within a designated surgical facility at UCLA. Hydrogel
brain injections were performed on mice under general anesthesia achieved
through inhalation of isoflurane in oxygen-enriched air. Prior to incision, the
mouse head was stabilized and horizontally leveled in a rodent stereotaxic appa-
ratus using ear bars (David Kopf, Tujunga, CA). A small craniotomy was per-
formed using a high speed surgical drill and visually aided by an operating
microscope (Zeiss, Oberkochen, Germany). Hydrogel injections were made in the
brain using pulled borosilicate glass micropipettes (WPI, Sarasota, FL, #1B100-4)
that were ground to a 35° beveled tip with 150–250 μm inner diameter. Glass
micropipettes were mounted to the stereotaxic frame via specialized connectors
and attached, via high-pressure polyetheretherketone tubing, to a 10 μL syringe
(Hamilton, Reno, NV, #801 RN) that was controlled by an automated syringe
pump (Pump 11 Elite, Harvard Apparatus, Holliston, MA). Each hydrogel was
backloaded into the micropipette prior to connecting to the stereotaxic frame. A
volume of 1 μL of hydrogel was injected into the CP nucleus at 0.15 μL/min using
target coordinates relative to Bregma: +0.5 mmA/P, +2.5 mm L/M and −3.0 mm
D/V. For the NGF delivery studies target coordinates relative to Bregma: +1 mm
A/P, + 2.2 mm L/M, and −3.0 mm D/V were used. The micropipette was allowed
to dwell in the brain at the injection site for an additional 4 min at completion of
hydrogel injection. The micropipette was then removed from the brain slowly and
incrementally over a 2 min period. After removal of the micropipette, the cra-
niotomy window was left unaltered while the incision site was sutured closed.
Animals were allowed to recover on a warm heating pad for 48 hours after surgery
with post-surgical buprenorphine (0.1 mg/kg) given every 12 h during this period.
To create focal ischemic strokes, 1 μL of L-NIO (N5-(1-Iminoethyl)-L-ornithine)
solution was injected into CP nucleus of the striatum using the same micropipette
injection protocol as above. The L-NIO solution was prepared by solubilizing
lyophilized L-NIO powder (Cat. No. 0546, Tocris) in sterile 1× PBS at a con-
centration of 27.4 mg/ml (130 µM). To create forebrain stab injuries, a 16 Gauge 1”
hypodermic needle was mounted to the stereotaxic frame and slowly lowered into
mouse brain at the same target coordinates outlined above. The needle was allowed
to dwell at the target coordinate location for 4 min and removed slowly thereafter.
To investigate hydrogel FBRs in the context of CNS injury, two separate
surgeries were performed. Firstly, to create large focal ischemic strokes 2 μL of L-
NIO solution was injected into CP nucleus of the striatum using the methods
described above. The animals were allowed to recover for 48 h before undergoing a
second surgery where 1 μL of DCH loaded with NGF (see specific formulation
details below) was injected into the same stereotactic location as the stroke lesion
using the same methods described above. After hydrogel injection the surgical
incision site was sutured closed and the animals were allowed to recover before
being transcardially perfused at 1 week after hydrogel injection.
Synthesis and formulation of hydrogels. Physically crosslinked hydrogels were
formulated from polypeptide or polysaccharide polymers (Fig. 1a, Supplementary
Fig. 3a, b) that were synthesized using procedures developed previously by our
group or purchased from commercial sources and used as received.
Preparation of diblock copolypeptide hydrogels (DCH): The polypeptides were
prepared using synthetic schemes reported previously. Specific and detailed
synthetic protocols for preparing DCHMO, DCHK, DCHMM, DCHE, DCHMOK10,
DCHMOE15 have been provided across a number of previous peer reviewed
publications8,25,34.
DCHMOE15 was prepared for the first time as part of this current work and the
method for synthesizing this polypeptide can serve as a general overview for
polypeptide synthesis. Polypeptide synthesis was performed in a N2 filled glove box
using anhydrous solvents. Amino acid N-carboxyanhydride (NCA) monomers
including tert-butyl-L-glutamate NCA, L-methionine NCA, L-leucine NCA were
prepared by phosgenation of a tetrahydrofuran (THF) solution of the
corresponding amino acid in a Schlenk flask under N2 and purified by either
recrystallization or column chromatography as outlined before. To prepare
copolypeptides at ca. 100 mg scale, a solution of initiator, Co(PMe3)4, (3.5 mg,
0.001 mmol) in THF (20 mg/mL) was quickly added to a mixture of L-methionine
NCA (Met NCA; 100 mg, 0.57 mmol) and tert-butyl-L-glutamate NCA (tert-butyl
Glu NCA; 23 mg, 0.10 mmol) in THF (50 mg/mL). After 2 h, complete
consumption of NCA was confirmed by Fourier transform infrared (FTIR)
spectroscopy. In order to determine the lengths of poly(L-methionine-stat-tert-
butyl-L-glutamate)m, (MEtB)m, segments, a small aliquot (200 µl) of
polymerization mixture was removed, reacted with α-methoxy-ω-isocyanoethyl-
poly(ethylene glycol)45 (mPEG23-NCO) and chain length determined by end-group
analysis using 1H NMR. To the remaining copolymerization mixture L-leucine
NCA (Leu NCA; 14 mg, 0.088 mmol) in THF (50 mg/mL) was then added. The Leu
NCA monomers were found to be completely consumed within ~1 h, and the
reaction mixture was subsequently removed from the glove box. The block
copolypeptide solution was then precipitated by addition to a DI water solution
(75 mL), filtered, washed with DI water, and dried under reduced pressure to
obtain a white fluffy solid (91 mg, 95% yield).
The deprotection of tert-butyl-L-glutamate residues was performed before the
oxidation of L-methionine residues. To facilitate deprotection, (MEtB)170L24 (ca. 80
mg) was fully dissolved in trifluoroacetic acid (ca. 25 mg/mL) and stirred at
ambient temperature for 16 h. The copolypeptide was then precipitated into diethyl
ether (75 mL). The diethyl ether was decanted and the copolypeptide was dried
under reduced pressure overnight to yield a white solid (ca. 74 g, 99% yield, 97%
deprotection efficiency). To convert L-methionine residues in copolypeptides to L-
methionine sulfoxide residues, a volume of 70 wt.% tert-butyl hydroperoxide (16
molar equivalents per L-methionine residue) was added to a sample of solid
copolypeptide (ca. 80 mg). The reaction mixture was then diluted with DI water to
yield an overall polypeptide concentration of 20 mg/mL. To aid oxidation, a
catalytic amount of camphorsulfonic acid (0.2 molar equivalents per Met residue)
solution in DI water (20 mg/ml) was subsequently added. The reaction mixture was
stirred vigorously for 24 h at ambient temperature, whereupon complete
dissolution of the copolypeptide sample was observed. Reaction mixtures were
transferred to 2000 MWCO dialysis bags and dialyzed against: (i) pyrogen-free
deionized milli-Q water (3.5 L) containing sodium thiosulfate (1.2 g, 2.2 mM) for
1 day to neutralize residual peroxide, (ii) pyrogen-free deionized milli-Q water (3.5
L) containing ethylenediaminetetraacetic acid tetrasodium salt hydrate (1.0 g, 2.63
mmol) to aid cobalt ion removal, (iii) pyrogen-free deionized milli-Q water (3.5 L),
which was adjusted to pH 8 with 1.0 M NaOH and contained sodium chloride (5 g,
85.5 mmol) for 2 days to aid in counter ion exchange of glutamate residues, and
(IV) pyrogen-free deionized milli-Q water (3.5 L) for 2 days to remove residual
ions. For each step dialysate was changed every 12 h. The copolypeptide solution
was then freeze dried to yield a white fluffy solid (ca. 85 g, 95% yield, and 100%
conversion of L-methionine residues in copolypeptides to L-methionine sulfoxide
groups).
All DCH variants were prepared by solubilizing lyophilized copolypeptide in
PBS and leaving to assemble for 24 h, without stirring, before use. All DCH
formulations were prepared at 4.0 wt% in PBS. All polymer chemical structures
were prepared using ChemDraw 18.2.
Preparation of polysaccharide-based hydrogels: Polysaccharide-based hydrogels
of chitosan, methylcellulose (MC) and HAMC were prepared following procedures
detailed in the literature. To formulate chitosan hydrogels, solutions of chitosan
[MW= 50,000–190,000 Da; DDA ≈ 85%] (Sigma, #448869) in 0.1 M acetic acid
were prepared at 2.3% (w/v) and allowed to dissolve overnight at 4 °C33. A 50% w/v
or 2.314 M solution of β-glycerophosphate disodium salt (Sigma, #G9422) in water
was subsequently added dropwise to the chitosan solution on ice and manually
stirred to form a uniform solution and elevate the solution pH to 7.4. Prior to
surgical micropipette loading, the chitosan hydrogel was incubated at 37 °C for
1 hour to initiate physical gelation. MC (Methocel A15C, [MW= 304 kDa;
27.5–31.5% substitution], Sigma #64625) hydrogels were prepared by dispersing
and then solubilizing at 4 °C at a concentration of 4 wt%31. The HAMC hydrogel
was prepared by dispersing a measured amount of hyaluronic acid [1.01–1.8 MDa]
(Lifecore Biomedical, #HA15M-1) into a pre-dissolved 4 wt% MC solution and
allowed to dissolve at 4 °C overnight. The HAMC blended hydrogel used for in vivo
studies had a concentration of 1% HA and 3% MC, which was equivalent that used
previously within in vivo CNS studies32.
For BDA delivery experiments, appropriate volumes of 10% w/v stock solutions
of BDA (10 kDa—Thermofisher, #D1956 or 70 kDa—Thermofisher, # D1957) in
PBS were added to the polymer solutions to net a final concentration of 1% BDA in
hydrogels. For NGF delivery experiments, lyophilized recombinant human β-NGF
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(PeproTech, Cat# 450-01, Rocky Hill, NJ) was reconstituted in PBS and added to
the polymers to form hydrogels with a final concentration of NGF of 1 mg/mL.
Microgel MP synthesis. MPs based on PEG microgels were derived by covalently
reacting ethoxylated trimethylolpropane oligomers functionalized with either
acrylate or thiol acid ester groups under physiologically buffered conditions by
thiol-ene Michael Addition as reported before58. A standard inverse emulsion
technique was applied to formulate microgels whereby aqueous buffer solubilized
oligomers were dispersed in a larger volume mineral oil bath that contained the
nonionic sorbitan alkyl ester surfactant, Span 83, to create a stable emulsion and
direct microgel size59,60. The emulsion was stirred for one hour at room tem-
perature on a magnetic stir plate before being washed and centrifuged three times
with hexanes to remove the mineral oil and surfactant. Collected MPs were dried
under high vacuum to evaporate residual hexane solvent. Microgels were uniformly
dispersed in PBS at 6 wt% using a pellet pestle mixer and added to hydrogel
solutions to a final concentration of 3 wt%. For BDA delivery experiments,
appropriate volumes of 10% BDA-10 stock were added to the aqueous reaction
buffer during microgel synthesis to load microgel particles with BDA.
Hydrogel and microparticle characterization. Dynamic mechanical rheology:
dynamic rheological measurements were performed at constant set temperature of
25 °C using a Physica MCR 301 (Anton Paar, Sweden) equipped with a 25 mm 1°
cone and plate geometry. To determine the linear viscoelastic testing region for
each DCH sample a frequency sweep from 0.1 to 100 rad s−1 at a fixed strain of
0.5% was applied followed by a strain sweep from 0.1 to 100% strain at a fixed
frequency of 10 rad s−1. DCH samples were allowed to recover for a period of 2
min between individual rheological experiments. To compare mechanical prop-
erties across various DCH samples a time sweep under fixed strain and frequency
conditions (0.5% strain and 10 rad s−1) was applied for one minute.
Zeta potential measurement: K170 (hydrophilic block of DCHK), (MOA)170
(hydrophilic block of DCHMO), and (MMA)170 (hydrophilic block of DCHMM),
were dissolved at 15 mg/mL in a 20 mM phosphate buffer solution at pH 7.4, which
was filtered through a 0.45 µm membrane syringe filter. Mean zeta potentials were
analyzed using a Zetasizer NanoZS instrument (Malvern Instruments Ltd., United
Kingdom). Samples were analyzed in monomodal mode where fast field reversal
technique was applied and the electrophoretic mobility was calculated using the
Henry equation. Sample were prepared in triplicate and analyzed three times.
FTIR: dried MPs were analyzed by FTIR to confirm the presence of the
crosslinked ethoxylated polyol network. Several milligrams of dried MPs were
analyzed by attenuated total reflection Fourier transform infrared (ATR‐FTIR)
spectroscopy using a PerkinElmer Spectrum One instrument equipped with a
universal ATR assembly. The ester stretch (≈ 1730 cm−1) and the loss of the
acrylate C= C stretch (1675–1600 cm−1) were used to confirm presence of the
covalent crosslinked network58.
Differential interference contrast microscopy: to visualize and quantify the size of
formulated MPs a 1 mg/ml solution of dispersed MPs was placed on a glass slide,
coverslipped and imaged on a Zeiss Axioplan photomicroscope using a ×63 oil
objective. Quantification of MPs size was performed on images taken from several
separately prepared slides using NIH Image J (1.51) software.
Immunohistochemistry. After terminal anesthesia by barbiturate overdose mice
were perfused transcardially with heparinized saline and 4% paraformaldehyde.
Brains were immediately dissected after perfusion and post-fixed in 4% paraf-
ormaldehyde for 6 h. Brains were cryoprotected in 30% sucrose in Tris-buffered
saline (pH= 7.4) (TBS) for at least 3 days with the sucrose solution replaced once
after 2 days. Coronal brain sections (40 µm thick) were cut using a Leica CM3050
cryostat. Brain sections were stored transiently in TBS buffer at 4°C or in antifreeze
solution of 50% glycerol/30% Sucrose in PBS at −20 °C for long-term storage.
Brain sections were processed for immunofluorescence using a free floating
staining protocol involving a 1 N Hydrochloric acid incubation for 10 min for
antigen retrieval, three washes with TBS buffer, a one hour incubation with 5%
donkey serum in TBS/0.5% triton X-100 solution to block and permeabilize tissue,
then an overnight incubation in primary antibody solution4,5. The primary anti-
bodies used in this study were: rabbit anti-GFAP (1:1000; Cat#Z-0334, Dako, Santa
Clara, CA); rat anti-GFAP (1:1000, Cat#13-0300, Clone-2.2B10, Thermofisher,
Grand Island, NY); rabbit anti-NeuN (1:1000, Cat#Ab177487, Clone-EPR12763,
Abcam, Cambridge, MA); guinea pig anti-NeuN (1:1000, Cat#266-004, Synaptic
Systems, Goettingen, Germany); goat anti-CD13 (1:200, Cat#AF2335, R&D sys-
tems, Minneapolis, MN); rabbit anti-Laminin 1 (1:100, Cat#L-9393, Sigma, St.
Louis, MO); rabbit anti-Fibronectin (1:500, Cat#AB2033, Millipore, Burlington,
MA); rabbit anti-Collagen-1a1 (1:300, Cat#NB600-408. Novus Biologicals, Lit-
tleton, CO); rabbit anti-RFP (1:1000, Cat#600-401-379, Rockland, Limerick, PA);
goat anti-Albumin (1:300, Cat#NB600-41532, Novus Biologicals, Littleton, CO); rat
anti-PECAM-1 (1:200, Cat#550274, clone-MEC 13.3 BD Biosciences, San Jose,
CA); rat anti-Galectin-3 (1:200, Cat#14-5301-82, Clone-M3/38, Invitrogen-
Thermofisher Scientific, Grand Island, NY); rat anti-CD68 (1:1000, Cat#
MCA1957, CLone-FA-11, AbDserotec-BioRad, Hercules, CA); rat anti-CD45
(1:100, Cat#553076, Clone-30-F11, BD Biosciences, San Jose, CA); rabbit anti-Iba-1
(1:800, Cat#019-19741, Wako, Osaka, Japan); guinea pig anti-Iba-1 (1:800,
Cat#234-004, Synaptic systems, Goettingen, Germany); Rabbit anti-P2Y12R (1:500,
Cat#AS-55043A, Anaspec, Fremont, CA); rabbit anti-mouse IgG (1:1000,
Cat#97042, Abcam, Cambridge, MA); rat anti-Ly6B2 (1:200, Cat#MCA771GT,
Clone-7/4, BioRad, Hercules, CA); Goat anti-PDGFR-β (1:200, Cat#AF1042, R&D
systems, Minneapolis, MN); and rabbit anti-Olig2 (1:200, Cat#AB9610, Millipore,
Burlington, MA). All secondary antibodies used in this study were purchased from
Jackson ImmunoResearch (West Grove, PA). Primary antibodies without a
designated clone are polyclonal. All primary antibodies used have been previously
validated by the manufacturer and confirmed by us for use on mouse paraf-
ormaldehyde fixed, frozen cut tissue (validated mouse reactivity) and for use in
fluorescent IHC applications. After overnight primary antibody incubation, tissue
sections were washed three times with TBS followed by incubation with secondary
antibodies in a solution containing 5% donkey serum for 2 h. All secondary anti-
bodies used in this study were purchased from Jackson ImmunoResearch (West
Grove, PA). All secondary antibodies were affinity purified whole IgG(H+ L)
antibodies with donkey host and target species dictated by the specific primary
antibody used. All secondary antibodies were stored in 50% glycerol solution and
diluted at a concentration of 1:250 in 5% normal donkey serum in TBS when
incubated with brain histological sections. BDA was visualized with streptavidin-
HRP plus Tyr-Cy3 (PerkinElmer)4. After removal of secondary antibody solution,
tissue sections were washed with TBS and nuclei were stained with 4’,6’-diamidino-
2-phenylindole dihydrochloride (DAPI; 2 ng/ml; Molecular Probes). Sections were
coverslipped using ProLong Gold anti-fade reagent (InVitrogen, Grand Island,
NY). Sections were examined and photographed using epifluorescence microscopy,
deconvolution fluorescence microscopy and scanning confocal laser microscopy
(Zeiss, Oberkochen, Germany). Tiled scans of individual whole sections were
prepared using a x20 objective and the scanning function of a Leica Aperio Versa
200 Microscope (Leica, Wetzlar, Germany) available in the UCLA Translational
Pathology Core Laboratory.
Quantification of IHC. Immunohistochemical staining intensity quantification was
performed on whole brain images derived from the slide scanner or tiled images
prepared on the epifluorescence microscope. All images used for each comparable
analysis were taken at a standardized exposure time and used the raw/uncorrected
intensity setting. Quantification of antibody staining intensity for the individual
hydrogels was performed using NIH Image J (1.51) software and the Radial Profile
Angle plugin. The procedure for determining the hydrogel radius and the non-
neural and neural compartments is outlined graphically in Supplementary Fig. 2. In
brief, a radial profile field of 900 µm (~846 pixels) was applied to each hydrogel
(this standardized radial profile field was determined as the average field that
included all hydrogels and was confined within the CP region of the brain section
(i.e., between the ventricle and corpus callosum)). The radial profile analysis
determines the average pixel intensity value across the circumference of a circle at
each radial pixel distance. The Hydrogel radius/start of tissue location was deter-
mined from the DAPI profile and specifically where the numerical first derivative
(ΔIntensity/Δr) of the DAPI profile crossed a threshold of +0.2. The non-neural/
neural tissue boundary was defined as the maximum of the GFAP intensity which
was determined where (ΔIntensity/Δr) equaled zero. All numerical first derivative
calculations were performed using Prism 8 (GraphPad Software Inc, San Diego,
CA). Total values for CD13, GFAP, Ly6B2, Col1a1, Gal-3, Albumin, IgG, Iba-1,
BDA stainings were determined by taking the integral (area under the curve) of the
radial intensity profile using Prism 8 software. Albumin and IgG intensities and
total values were normalized to the contralateral hemisphere of each animal.
For BDA and NGF delivery quantification only slide scanned images were used.
Medial and lateral hem-circular radial analysis was performed in addition to the
standard radial profile analysis described above to quantify BDA dispersion
throughout whole brain sections. Quantification of the co-staining of BDA with
specific immunohistochemical stains such as NeuN, CD13, CD68, Iba-1, IgG, and
albumin was performed using the RG2B colocalization plugin in NIH Image J
(1.51) software. Number of BDA and NeuN-positive neurons was determined by
counting the number of BDA/NeuN colocalized staining puncta using the analyze
particles function in NIH Image J (1.51) software. Bioactive NGF delivery was
assessed by characterizing the size (area) of choline acetyltransferase (ChAT) and
NeuN-positive cholinergic neurons also using the analyze particles function in NIH
Image J (1.51) software. Orthogonal (3D) images were prepared using Imaris 9.2
(Bitplane).
Statistics, power calculations, group sizes, and reproducibility. Graph gen-
eration and statistical evaluations of repeated measures were conducted by one-way
or two-way analysis of variance (ANOVA) with post hoc independent pair wise
analysis as per Bonferroni, Tukey, or by Student’s t-tests (two-sided) where
appropriate using Prism 8 (GraphPad Software Inc, San Diego, CA) and Microsoft
Excel (Microsoft Office 365 ProPlus). PCA was performed using XLStat (Addinsoft
Inc, Long Island City, NY). For one-way and two-way ANOVA statistical eva-
luations, P values, F values, and degrees of freedom are reported in the manuscript
and within the source data files. Similarly, for Student’s two-tailed t test, the t value
and degrees of freedom are reported. Power calculations were performed using
G*Power Software V 3.1.9.2. For immunohistochemical quantification analysis,
group sizes were calculated to provide at least 80% power when using the following
parameters: probability of type I error (alpha)= 0.05, a conservative effect size of
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0.25, 3–10 treatment groups with multiple measurements obtained per replicate.
All graphs show mean values plus or minus standard error of the means (s.e.m.) as
well as individual values as dot plots. All bar graphs are superimposed with dot
plots where each dot represents the value for one animal to show the distribution of
data and the number (n) of animals per group. In all images the specific number of
mice used per group is specified in the figure legend. Files of all individual values
and statistical analysis are provided as source data. Injections of hydrogel for-
mulations were repeated independently at least three times in different cohorts of
mice across a 3-year period and were reproduced with similar results. All data
derived from independent replications has been included in the data presented.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated for this study are included in the main and supplementary
figures. Other data that support the findings of this study are available on reasonable
request from the corresponding author. Source data are provided with this paper.
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